US Prevalence
15–50
Cases per million adults. PAH remains a rare disease, but the treatment revolution has dramatically increased the prevalent population as patients live longer with combination therapy.[1]
What Is It
Definition, mechanism, and the clinical reality of end-stage pulmonary arterial hypertension at end of life. What the hospice team needs to understand on day one.
Pre-Treatment Median Survival
2.8 yr
Historical median survival from the NIH registry (1981–1985) before the advent of PAH-targeted therapy. The diagnosis was essentially a death sentence.[2]
Modern Median Survival
5–10+ yr
Contemporary registries (REVEAL, COMPERA) document 5-year survival of 50–70% with combination therapy. WHO FC IV at presentation still carries >50% 1-year mortality.[3]
Female Predominance
3–4:1
Female-to-male ratio in idiopathic PAH. The typical PAH patient is a woman in the third to fifth decade of life — the hospice population is decades younger than average.[4]
Pulmonary arterial hypertension (PAH) is a devastating vasculopathy of the small pulmonary arteries characterized by intimal proliferation, medial hypertrophy, plexiform lesion formation, and in situ thrombosis that progressively obliterates the pulmonary vascular bed, drives pulmonary vascular resistance (PVR) to unsustainable levels, and forces the right ventricle to pump against a pressure load it was never designed to handle. PAH is classified under WHO Group 1 pulmonary hypertension, defined by right heart catheterization (RHC) showing mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg (excluding left heart disease), and PVR >3 Wood units. The Group 1 subtypes include idiopathic PAH (IPAH, ~50% of cases), heritable PAH (HPAH, most commonly BMPR2 mutation), connective tissue disease-associated PAH (CTD-PAH, with systemic sclerosis carrying the worst prognosis), congenital heart disease-associated PAH (Eisenmenger syndrome — see Card #68), and drug/toxin-induced PAH.[1][5]
The treatment revolution that began with IV epoprostenol in 1991 has transformed PAH from a rapidly fatal disease into a manageable chronic condition for many patients. Four drug classes — prostacyclin pathway agents, endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5i), and soluble guanylate cyclase (sGC) stimulators — and more than 14 approved agents now exist. Combination therapy with upfront dual or triple therapy has become the standard of care based on the AMBITION trial and subsequent registry data. But at end stage — WHO Functional Class IV, when the patient is dyspneic at rest, when syncope has begun, when the 6-minute walk distance has fallen below 165 meters despite maximal therapy — the right ventricle has reached the point of irreversible failure. The RV that has been compensating through hypertrophy for years has dilated, the interventricular septum has shifted leftward, LV filling is compromised through ventricular interdependence, and cardiac output has fallen to levels that produce the fatigue, syncope, renal impairment, and hepatic congestion that define the terminal phase.[3][6]
The hospice clinician who walks into the home of a patient with end-stage PAH is entering the most pharmacologically complex cardiovascular environment in all of hospice medicine. The patient may have an IV prostacyclin pump with a half-life measured in minutes, oral combination therapy that cannot be stopped abruptly, an ICD that may need deactivation, and a disease whose volume management paradox — the preload-dependent RV that simultaneously cannot tolerate volume overload — requires precision diuresis rather than the aggressive diuresis of left-sided heart failure. Every clinical decision must be specific to the physiology of the failing right heart.[7]
🧭 Clinical framing
The three things that define every PAH hospice visit: (1) The prostacyclin pump must be verified before anything else — dose, cassette, battery, catheter, home infusion contact. The pump that fails without a plan kills within minutes for epoprostenol. (2) The volume status must be assessed through the lens of the preload-dependent RV — not through the lens of left heart failure. Over-diuresis is as dangerous as under-diuresis. (3) The medication list must be treated as a hemodynamic life-support system — no PAH medication should be stopped or modified without PAH specialist guidance, because rebound vasoconstriction from abrupt withdrawal of sildenafil, bosentan, or any ERA/PDE5i can precipitate acute RV failure.
"The first time I walked into a PAH patient's home, I saw the backpack and I didn't know what it was. That was the most dangerous moment of the entire enrollment — because if I had accidentally disconnected that line, she would have coded in front of me. Now the pump check is the first thing I do. Before vitals, before the med rec, before I sit down. Check the pump. Every time."
— Waldo, NP · Terminal2
How It's Diagnosed
Right heart catheterization as the diagnostic gold standard. Hemodynamic parameters, echocardiographic assessment, vasoreactivity testing, and what to look for in hospice records.
PAH diagnosis requires right heart catheterization (RHC) — there is no substitute. Echocardiography provides screening estimates of pulmonary pressures but cannot confirm PAH or distinguish Group 1 from Group 2 PH. By the time a patient reaches hospice, the diagnostic RHC has been performed — often years ago — and subsequent serial RHCs have documented disease progression. The hospice clinician's role is to read and interpret prior hemodynamic data, not to order new testing, but understanding the numbers is essential for clinical decision-making.[8]
RHC Hemodynamic Parameters
- mPAP (mean pulmonary artery pressure): Normal <20 mmHg; PAH defined as >20 mmHg; end-stage typically >50–60 mmHg. The higher the mPAP, the greater the RV afterload.
- PCWP (pulmonary capillary wedge pressure): Must be ≤15 mmHg to confirm pre-capillary PH (Group 1 PAH). PCWP >15 mmHg = left heart disease (Group 2 PH) — entirely different management.
- PVR (pulmonary vascular resistance): >3 Wood units required for PAH diagnosis; end-stage typically >15–30 Wood units. Reflects the degree of vascular obliteration.
- Cardiac Index (CI): CI <2.0 L/min/m² indicates severely reduced RV output and hospice-level prognosis.[9]
- SvO₂ (mixed venous oxygen saturation): <60% indicates severely limited oxygen delivery — advanced RV failure with inadequate forward flow.
- RAP (right atrial pressure): Elevation >15 mmHg indicates severe RV failure with systemic venous congestion.
Echocardiographic Assessment at Enrollment
- RVSP estimation: From TR jet velocity using modified Bernoulli equation; correlates with but is not identical to mPAP.
- RV size and function: TAPSE (tricuspid annular plane systolic excursion) <15 mm = severe RV dysfunction; RV dilation with IVS bowing = maladaptive remodeling.
- Pericardial effusion: Present in ~25% of advanced PAH; an independent predictor of mortality; indicates elevated RAP and poor prognosis.[10]
- RV/LV ratio: >1.0 indicates RV dominance with septal shift — hallmark of advanced PAH.
- RA dilation: Severely dilated RA correlates with elevated RAP and systemic venous congestion.
📋 Hospice Records Checklist for PAH
- Most recent RHC report: mPAP, PCWP, PVR, CI, SvO₂, RAP — and the trend from diagnosis to most recent catheterization
- Vasoreactivity testing result: Performed at initial RHC; ~10–15% of IPAH patients are vasoreactive; the vast majority are not — this determines CCB eligibility
- Most recent echocardiogram: RVSP, TAPSE, RV size, pericardial effusion, RV/LV ratio
- 6-minute walk test (6MWT) trend: Progressive decline below 165 m supports hospice eligibility
- BNP/NT-proBNP trend: Rising trajectory indicates progressive RV failure
- Prostacyclin pump details: Drug, dose (ng/kg/min), pump model, home infusion company, cassette schedule
- Complete PAH medication list: Drug names, doses, prescribing PAH center, specialist contact
- PAH subtype: IPAH, HPAH (BMPR2 status), CTD-PAH, CHD-PAH — subtype affects prognosis and family counseling
- Transplant evaluation status: Listed, evaluated and declined, not evaluated — affects goals-of-care discussions
💡 For families
The diagnosis of pulmonary hypertension was made with a special heart catheterization procedure, usually years ago. The doctors have been tracking the pressures in the lungs and how well the right side of the heart is working through follow-up tests. At this point, all the diagnostic work is complete — the focus now is entirely on comfort and supporting your person's quality of life with the treatments already in place.
Causes & Risk Factors
PAH pathogenesis, the BMPR2 mutation, plexiform lesions, and the RV adaptation-to-failure sequence. Why this matters for family conversations and genetic counseling referrals.
The molecular cascade that drives PAH begins with endothelial dysfunction — reduced production of vasodilatory mediators (nitric oxide via eNOS, prostacyclin via prostacyclin synthase) and excess production of vasoconstrictive mediators (endothelin-1, thromboxane A₂). This imbalance creates a pro-proliferative, pro-thrombotic, and vasoconstrictive environment in the small pulmonary arteries. The loss of the normal endothelial barrier allows platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and fibroblast growth factor-2 (FGF-2) to drive smooth muscle cell proliferation and migration into the intima, producing the characteristic concentric intimal thickening, medial hypertrophy, and ultimately the plexiform lesion — the pathognomonic vascular lesion of PAH, consisting of a channel-like proliferation of smooth muscle and endothelial cells within an obstructed arterial lumen. These plexiform lesions are irreversible. Current PAH therapies slow the development of new lesions but cannot reverse established structural damage.[11][12]
PAH Subtypes & Risk Factors
- Idiopathic PAH (IPAH): No identifiable cause; ~50% of PAH cases; female predominance 3–4:1; peak onset age 30–50
- Heritable PAH (HPAH): BMPR2 mutation in ~75% of familial PAH and ~20% of apparently sporadic IPAH; autosomal dominant with reduced penetrance (~10–20% of carriers develop PAH)
- CTD-PAH: Systemic sclerosis (SSc-PAH) is the most common and has the worst prognosis of all subtypes; also SLE, RA, mixed CTD
- CHD-PAH (Eisenmenger): Shunt reversal from long-standing L→R shunt; see Card #68
- Drug/toxin-induced: Fenfluramine/phentermine, methamphetamine, dasatinib, SSRIs (rare)
- HIV-associated PAH: Independent of CD4 count or viral load
RV Adaptation → Failure Sequence
- Stage 1 — RV Hypertrophy (Adaptive): RV wall thickens to maintain coupling with elevated PA pressure; cardiac output maintained; WHO FC I–II; the patient is compensated
- Stage 2 — RV Dilation (Maladaptive): RV-PA uncoupling begins; IVS bows leftward; LV filling impaired through ventricular interdependence; WHO FC III; symptoms emerge
- Stage 3 — RV Failure (End-Stage): Low cardiac output; systemic venous congestion; hepatic congestion; renal impairment; syncope; WHO FC IV; the terminal pathway[13]
❤️ For families: "Why did this happen?"
In most cases of PAH, there is no single identifiable cause. The blood vessels in the lungs gradually thickened and narrowed over time, forcing the right side of the heart to work harder and harder until it could no longer keep up. This was not caused by anything your person did wrong — not by diet, not by exercise habits, not by lifestyle choices. In some families, a genetic change (called BMPR2) can be inherited and increase the risk, but even then, most carriers never develop the disease. The important thing now is that we understand the disease well enough to manage symptoms and keep your person comfortable.
⚕ Clinician note: BMPR2 Genetic Counseling — An Obligation at Enrollment
BMPR2 mutation is present in approximately 75% of familial PAH and 20% of sporadic IPAH. The inheritance pattern is autosomal dominant with reduced penetrance (~10–20% of carriers develop clinical PAH). The clinical implication: first-degree relatives of any patient with IPAH or known HPAH have a 5–10% absolute lifetime risk of developing PAH if they carry the mutation. Genetic counseling referral at hospice enrollment is a clinical obligation — it must happen before the patient's death removes the opportunity for family testing. Early identification of BMPR2 carriers in first-degree relatives allows echocardiographic screening, early detection, and early treatment that dramatically improves survival. Document the referral and the family's response.[14][15]
Treatments & Procedures
End-stage PAH comfort management — the most pharmacologically complex clinical framework in all of cardiology hospice. Prostacyclin pump management, PDE5i, ERA, sGC, and the comfort transition.
🚨 PROSTACYCLIN PUMP — The First and Most Urgent Clinical Act at Every PAH Visit
The prostacyclin infusion verification protocol must be performed at every visit before any other clinical assessment. Epoprostenol has a half-life of 2–3 minutes. Treprostinil IV has a half-life of ~4 hours. An accidental interruption of the epoprostenol infusion produces catastrophic hemodynamic collapse within minutes. This is the most time-critical device safety act in all of hospice medicine.
5-Step Prostacyclin Pump Verification Protocol
Grade A — Clinical Obligation- Step 1 — Drug Dose: Confirm current dose in ng/kg/min matches the prescription. The patient on years of IV epoprostenol may be at 30, 50, or >80 ng/kg/min. This dose cannot be reduced without specialist guidance — it represents the minimum dose maintaining current hemodynamic status.[16]
- Step 2 — Cassette: Verify preparation date, expiration, fill volume, and that a backup cassette is present and in date. Epoprostenol (Flolan) requires refrigerated preparation fresh daily or q48h; Veletri is room-temperature stable for 72 hours. Treprostinil cassettes last up to 72 hours.
- Step 3 — Battery: Confirm charge level >50% on the primary battery. Confirm backup battery is present and fully charged. Know the alarm protocol — what sounds when battery is low and what to do when the "end of battery" alarm activates.
- Step 4 — Catheter: Inspect the Hickman catheter or port site — entry site, last dressing change date, signs of infection. CRBSI in the prostacyclin line is a potentially fatal emergency because the line cannot be removed without alternative venous access for the prostacyclin.[17]
- Step 5 — Home Infusion Company: Confirm the 24-hour emergency contact is accessible and the cassette delivery schedule is current. Post the number at the bedside.
PDE5 Inhibitor Management
- Sildenafil (Revatio): 20 mg TID; do NOT stop abruptly — rebound pulmonary vasoconstriction within hours. ⚠ ABSOLUTELY CONTRAINDICATED with nitrates. Dose adjustment if on bosentan (CYP3A4 inducer reduces sildenafil levels).[18]
- Tadalafil (Adcirca): 40 mg daily; same nitrate contraindication; longer half-life allows once-daily dosing; same rebound risk on abrupt withdrawal
ERA Management
- Bosentan (Tracleer): Dual ERA; CYP3A4 and CYP2C9 inducer — reduces sildenafil, warfarin, and many supplement levels; monthly LFTs required; hepatotoxicity risk; do not stop abruptly — endothelin-1 rebound vasoconstriction.[19]
- Macitentan (Opsumit): 10 mg daily; ERA with fewer CYP interactions than bosentan; monitor Hgb (anemia risk); do not stop abruptly
- Ambrisentan (Letairis): 5–10 mg daily; selective ERA-A receptor; peripheral edema common; do not stop abruptly
sGC Stimulator & Oral Prostacyclin
- Riociguat (Adempas): sGC stimulator; ⚠ ABSOLUTELY CONTRAINDICATED with PDE5i — the combination addresses the same pathway and produces severe additive hypotension. If both are present in the medication list, call the PAH specialist immediately.[20]
- Selexipag (Uptravi): Oral IP receptor agonist (prostacyclin pathway); headache, jaw pain, nausea, diarrhea common; do not stop abruptly
Comfort Transition — The Pump Decision
At what point does the burden of the prostacyclin pump exceed its benefit? This is a PAH specialist-guided decision made collaboratively with the patient and family. The pump that maintained hemodynamic stability for years may, at the terminal stage, become a source of suffering — the alarms, the cassette changes, the site care, the tethering to a device. The transition from the pump is not "giving up" — it is recognizing that the disease has progressed beyond what the pump can provide. When this decision is made, the prostacyclin dose is gradually weaned over hours to days under specialist supervision, with comfort medications (morphine, midazolam) titrated to manage the hemodynamic consequences. This conversation should happen early in the hospice enrollment, not during a crisis.[21]
When Therapy Makes Sense
Evidence-based criteria for continuing PAH-directed therapy at hospice enrollment. In PAH, medication continuation IS comfort care — stopping medications causes harm.
Unlike most hospice diagnoses where disease-directed therapy is discontinued at enrollment, PAH medications are comfort medications. Stopping them produces acute hemodynamic decompensation — not a gradual decline, but an emergency. The entire PAH medication regimen should be continued at enrollment unless the PAH specialist specifically advises otherwise.[22]
- 01Prostacyclin pump emergency protocol verified and documented at enrollment: The pump model, the dose, the cassette and battery status, the home infusion company emergency contact, and the family training on pump alarm response — all documented before any other clinical assessment. Never allow the prostacyclin infusion to stop at the first visit or any subsequent visit without immediately addressing the cause.[16]
- 02PAH specialist co-management established at enrollment: The PAH center that has been managing this patient has disease-specific knowledge the hospice team cannot replicate. Contact the PAH center before the first hospice visit. Establish a communication protocol for clinical questions. Document the specialist name and contact in the first line of the care plan.
- 03All PAH medications continued at current doses: PDE5i, ERA, sGC stimulator, oral/inhaled prostacyclin — all continued unless the PAH specialist provides specific guidance to modify. These medications are maintaining the patient's hemodynamic equilibrium. Stopping any of them produces rebound vasoconstriction and acute decompensation.
- 04Precision diuresis at the minimum effective dose: Furosemide 20–40 mg daily starting dose with weekly BMP and clinical assessment. Not the aggressive diuresis of left heart failure. The preload-dependent RV requires enough filling pressure to maintain output — over-diuresis causes worsening fatigue, hypotension, and rising creatinine.[23]
- 05
- 06Syncope advance directive at enrollment: Specifically ask about hospitalization preference for syncope, CPR preference for syncope-to-arrest, and ICD deactivation decision. The syncope that occurs without a documented advance directive results in 911 activation and potentially unwanted interventions.
- 07BMPR2 genetic counseling referral at enrollment: For all heritable or idiopathic PAH patients — before the patient's death. The family's first-degree relatives have a 5–10% absolute risk of developing PAH if they carry the mutation. Early detection saves lives. Document the referral and the family's response.[14]
- 08ICD deactivation conversation at enrollment: The ICD that delivers shocks during the dying process causes suffering without benefit. The conversation about magnet placement or device deactivation should happen at enrollment, not in the final hours. Document the decision.
When It Doesn't
Interventions that cause harm in end-stage PAH. The contraindications that are absolute, the medication errors that kill, and the clinical decisions that make PAH patients worse.
PAH medication management contains more absolute contraindications, more drug interactions, and more potential for iatrogenic catastrophe than any other cardiovascular hospice diagnosis. The errors described below are not theoretical — they are the errors that occur when clinicians unfamiliar with PAH apply left-heart-failure or general hospice frameworks to a right-heart-failure disease with unique physiology.[26]
- 01NEVER stop any PAH medication without PAH specialist guidance: Sildenafil, tadalafil, bosentan, macitentan, ambrisentan, riociguat, selexipag — all produce rebound pulmonary vasoconstriction on abrupt withdrawal. Sildenafil stopped abruptly produces acute RV decompensation within hours. Bosentan stopped produces endothelin-1 vasoconstriction rebound. None of these medications should be stopped at hospice enrollment without explicit PAH specialist guidance and a plan for managing hemodynamic consequences.[18]
- 02NEVER prescribe any nitrate to a patient on sildenafil or tadalafil: ⚠ ABSOLUTELY CONTRAINDICATED. The sildenafil-nitrate combination produces catastrophic hypotension through additive PDE5 and nitrate-mediated vasodilation. This includes nitroglycerin, isosorbide mononitrate, isosorbide dinitrate. Post this as prominently as morphine contraindication in ESRD and NSAIDs in SSc.[27]
- 03NEVER prescribe riociguat with sildenafil or tadalafil: ⚠ ABSOLUTELY CONTRAINDICATED. These two medications address the same NO-sGC-cGMP signaling pathway through different mechanisms and their combination produces additive severe hypotension. If both appear in the medication list, call the PAH specialist immediately.
- 04NEVER aggressively diurese targeting "ideal dry weight" using left-heart-failure frameworks: The PAH patient who is over-diuresed develops low-output state from inadequate RV preload. The diuresis that reduces peripheral edema but simultaneously reduces RAP below 8 mmHg has made the patient worse, not better. Signs of over-diuresis: worsening fatigue, hypotension, rising creatinine. Monitor after every diuretic adjustment.[23]
- 05NEVER prescribe calcium channel blockers for PAH vasodilation without confirmed vasoreactivity: Only ~10–15% of IPAH patients are vasoreactive. The non-vasoreactive patient who receives CCB therapy develops profound hypotension and acute RV failure. CCBs are absolutely contraindicated in non-vasoreactive PAH, in CTD-PAH, in CHD-PAH, and in any patient on prostacyclin therapy.
- 06NEVER reduce the epoprostenol dose without PAH specialist guidance: The dose that was established after years of carefully monitored escalation represents the minimum dose maintaining the patient's current hemodynamic status. Any dose reduction without specialist guidance and hemodynamic monitoring risks catastrophic vasoconstriction and RV failure.[16]
- 07NEVER use high-flow supplemental oxygen in Eisenmenger syndrome without specialist guidance: In Eisenmenger physiology, excessive oxygen can reduce pulmonary vascular resistance and potentially worsen the shunt. Oxygen should target SpO₂ 85–90%, not room-air normal saturations.
📋 Clinician note — The False Binary
PAH hospice enrollment is NOT "stopping treatment." The PAH medications ARE the comfort care. The prostacyclin pump IS the comfort device. The referral conversation with the PAH specialist should frame hospice as "adding a layer of support that includes symptom management, family support, and goals-of-care planning — while continuing all PAH-directed therapy." The family who hears "we're stopping treatment" will resist hospice enrollment. The family who hears "we're adding comfort support while continuing everything that's been working" will engage.
Out-of-the-Box Approaches
Evidence-graded integrative and interventional approaches specific to end-stage PAH. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Prostacyclin Pump Verification Protocol
Grade A5-step check at every nursing visit: dose → cassette → battery → catheter → infusion company
The most specific and most urgent device safety act in all of hospice medicine. The epoprostenol half-life of 2–3 minutes and the treprostinil IV half-life of ~4 hours define the therapeutic window that makes the prostacyclin pump the most time-critical device in hospice. Family training must include: recognizing pump alarms and their meaning, performing the emergency cassette change, troubleshooting the battery alarm, and the 3-step emergency response — (1) attempt restart within 5 minutes, (2) call the infusion company, (3) call 911 if not resolved within 15 minutes with written notification that IV prostacyclin failure is occurring. The family who cannot demonstrate this competency before the first hospice visit ends has not been adequately prepared.[16][17]
REVEAL 2.0 Risk Score for Hospice Documentation
Grade AValidated prognostic calculator incorporating WHO FC, 6MWT, BNP, hemodynamics, and clinical variables
The REVEAL 2.0 risk score is the validated prognostic instrument that supports the 6-month prognosis certification for PAH hospice enrollment. It stratifies 1-year mortality risk: low risk (<5%), intermediate risk (5–10%), high risk (>10%). A REVEAL 2.0 score in the high-risk category, combined with WHO FC IV and failing maximal therapy, provides the evidence-based documentation for hospice eligibility. Use at enrollment and at every recertification. Document the specific score and its components in the clinical record.[3][9]
Precision Diuresis Algorithm
Grade BFurosemide 20–40 mg PO daily; BMP weekly; clinical reassessment after every dose change
The PAH-specific diuresis algorithm uses JVP assessment, BNP trend, renal function, and clinical symptoms (fatigue, orthopnea, edema) as guides. The target is not "dry weight" but "optimal preload" — the volume status that provides adequate RV filling without causing RV distension and IVS shift. If the patient becomes more fatigued after a diuretic increase, the dose is too high. Reduce and reassess. Spironolactone 25 mg daily as adjunct for aldosterone-mediated sodium retention and potential RV remodeling benefit.[23][28]
Fan Therapy for PAH Dyspnea
Grade AHandheld or bedside fan directed at cheeks and nasal area; continuous or PRN during dyspnea episodes
Galbraith et al. (2010) demonstrated that a handheld fan directed at the face reduces dyspnea perception through trigeminal nerve (V2/V3) stimulation — strong evidence applicable across diagnoses including PAH. Prescribe as a formal clinical order at enrollment. The fan is free, has no drug interactions, no side effects, and no contraindications in PAH. It is the most underutilized comfort intervention in hospice medicine.[25]
Low-Dose Morphine for PAH Dyspnea
Grade AMorphine 2.5 mg PO q4h PRN; titrate conservatively from hemodynamic sensitivity
Abernethy et al. (2003) established that low-dose sustained-release morphine reduces chronic dyspnea in a landmark placebo-controlled RCT. In PAH, start at 2.5 mg — lower than the typical COPD starting dose — because the hemodynamically compromised RV is more sensitive to the vasodilatory effects of opioids. Titrate based on dyspnea response and hemodynamic tolerance. Morphine also reduces pulmonary vascular resistance slightly, which is beneficial in PAH.[24]
Spironolactone for RV Remodeling
Grade CSpironolactone 25 mg PO daily; monitor K⁺ weekly initially
Emerging preclinical and observational evidence suggests spironolactone may attenuate RV fibrosis and remodeling through aldosterone receptor blockade, similar to its proven benefit in LV failure. Additional benefit as potassium-sparing diuretic reducing hypokalemia risk in patients on loop diuretics. Monitor potassium carefully, especially in patients with renal impairment from low cardiac output.[28]
PAH-Specific Palliative Care Model
Grade BConcurrent PAH specialist + hospice team from enrollment; shared decision-making framework
The PAH-specific palliative care model integrates hospice services while maintaining PAH specialist co-management — fundamentally different from the oncology model where disease-directed therapy is typically discontinued. This model has been described in multiple observational cohorts and consensus statements. The key: the PAH specialist remains the medication manager while the hospice team manages symptoms, psychosocial support, and goals-of-care planning.[29][30]
Music Therapy for PAH Anxiety
Grade CBoard-certified music therapist; 30–45 minute sessions 1–2× weekly; patient-preferred genre
Limited PAH-specific data, but RCT evidence from cardiac and pulmonary populations demonstrates that music therapy reduces anxiety, reduces perceived dyspnea, and may reduce heart rate and blood pressure. Particularly valuable for the young PAH population where anxiety is pervasive and pharmacological anxiolysis carries hemodynamic risk. Refer at enrollment.[31]
Natural & Herbal Options
Evidence grading, dosing, and the most dangerous supplement interaction landscape in all of hospice medicine. Three non-negotiable safety principles for every supplement assessment in PAH.
🚨 Three Non-Negotiable Safety Principles for Supplements in PAH
- (1) Sildenafil/Tadalafil + Nitrates — ABSOLUTELY CONTRAINDICATED: Any supplement with vasodilatory nitrate-like properties combined with PDE5i produces catastrophic hypotension. This includes supplements marketed as "cardiovascular support" or "blood flow support" containing nitric oxide precursors (L-arginine, L-citrulline), beet root extract, or similar NO-pathway activating compounds.
- (2) Bosentan CYP Induction: Bosentan is a CYP3A4 and CYP2C9 inducer — it reduces levels of drugs metabolized by these enzymes and affects numerous supplements. Every supplement in a patient on bosentan requires CYP interaction assessment.
- (3) Prostacyclin Antiplatelet Effect: Epoprostenol, treprostinil, and iloprost have significant antiplatelet activity through IP receptor activation. Supplements with additional antiplatelet activity (omega-3s at high doses, garlic, ginkgo, vitamin E at high doses) add to this effect and increase bleeding risk.
"The PAH patient's family is often young, health-conscious, and researching supplements online at 2 AM. They will bring things into the home. Your job isn't to say no to everything — it's to know which supplements are genuinely dangerous with these specific medications. The L-arginine with sildenafil conversation isn't optional. It's a safety conversation."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Coenzyme Q10 | Grade C | 100–300 mg daily | Mitochondrial support in the energy-limited RV; antioxidant; may support myocardial ATP production in the pressure-overloaded RV | Generally safe; may slightly reduce INR in warfarin patients (monitor); no significant interaction with PDE5i, ERA, or prostacyclin; one of the safer supplements in PAH[32] |
| Magnesium | Grade C | 200–400 mg daily (glycinate or citrate) | Vasodilatory effect; muscle cramp reduction; arrhythmia prophylaxis in hypokalemic/hypomagnesemic states | Caution with renal impairment from low cardiac output; monitor Mg²⁺ levels; avoid magnesium oxide (poor absorption); mild vasodilatory effect may be additive with PDE5i — monitor BP |
| L-Carnitine | Grade C | 1–2 g daily | Fatty acid transport for myocardial energy production; small studies suggest improvement in exercise tolerance in heart failure | Generally safe in PAH; may cause GI upset; no significant drug interactions with PAH medications; monitor for fishy body odor at high doses |
| Iron (IV or PO) | Grade B | Target ferritin >100 ng/mL; iron saturation >20% | Iron deficiency is present in ~40–60% of PAH patients and independently impairs exercise capacity and RV function; correction improves 6MWT and WHO FC | IV iron preferred in severe PAH due to GI absorption issues; coordinate with PAH specialist; do not give through the prostacyclin line[33] |
| Melatonin | Grade C | 1–5 mg QHS | Sleep regulation; antioxidant; preliminary evidence of pulmonary vasodilatory effect in animal models; addresses the pervasive sleep disruption from pump alarms and nocturnal dyspnea | Generally safe; may interact with warfarin (minor INR increase); mild hypotensive effect — monitor in hemodynamically fragile patients; improves sleep quality without benzodiazepine risks |
| Omega-3 Fatty Acids | Grade C | 1–2 g daily (EPA+DHA) | Anti-inflammatory; may reduce pulmonary vascular inflammation; cardioprotective effect in heart failure populations | ⚠ Antiplatelet effect at high doses — additive with prostacyclin antiplatelet activity; keep dose ≤2 g daily; monitor for bruising/bleeding; avoid concomitant high-dose vitamin E[34] |
| Vitamin D | Grade C | 1000–4000 IU daily; target 25(OH)D >30 ng/mL | Vitamin D deficiency is highly prevalent in PAH (~70–90%); deficiency correlates with worse functional class; repletion may improve immune function and reduce inflammation | Generally safe; monitor calcium in patients with hepatic congestion; no significant interaction with PAH medications; may require higher doses due to hepatic congestion impairing hydroxylation |
🚫 Absolutely Avoid in PAH
- L-Arginine / L-Citrulline / Beet Root Extract / NO Precursors: These are nitric oxide pathway activators. In combination with sildenafil or tadalafil, they produce the same catastrophic hypotension as nitrate drugs. NO EXCEPTIONS — regardless of the "natural" marketing.
- Ginkgo Biloba: Antiplatelet effect additive with prostacyclin; CYP3A4 substrate affected by bosentan induction; bleeding risk unacceptable in patients on prostacyclin therapy.
- High-Dose Garlic (>4 g/day): Significant antiplatelet activity additive with prostacyclin; CYP3A4 interactions; blood pressure reduction additive with PDE5i.
- St. John's Wort: Potent CYP3A4 inducer — reduces sildenafil, bosentan, and warfarin levels unpredictably. Absolutely contraindicated in any patient on PAH combination therapy.
- Ephedra / Ma Huang: Sympathomimetic vasopressor effect; may increase pulmonary vascular resistance; contraindicated in PAH.
Timeline Guide
A guide, not a prediction. The PAH trajectory is shaped by subtype, treatment response, RV adaptation, and the prostacyclin pump that has kept many patients alive for years longer than the pre-treatment era predicted.
The PAH timeline is characterized by the long diagnostic odyssey — the woman who was exercising normally before her first symptoms, who was misdiagnosed with asthma or anxiety for 2–3 years before PAH was diagnosed, who then had a period of treatment-mediated stabilization that lasted years, and who now at WHO FC IV has been fighting this disease for a decade or more. Every phase below represents a real chapter in the patient's life, and the hospice clinician who understands the full arc can provide more meaningful care.[2][35]
YRS
1–4
1–4
Phase 1 — Onset & Misdiagnosis
- First symptoms: exertional dyspnea and fatigue attributed to deconditioning, anxiety, or asthma — the 2–4 year average delay from symptom onset to PAH diagnosis documented in every major registry
- The echocardiogram that showed elevated RVSP led to the RHC that established the diagnosis
- The reaction to the diagnosis — the devastating news of a condition whose prognosis, even in the modern era, is measured in years rather than decades
- The pregnancy counseling conversation: PAH carries 30–50% maternal mortality — the family planning decision that changed the reproductive future
YRS
3–10
3–10
Phase 2 — Treatment & Relative Stabilization
- Oral combination therapy initiated — dual or triple therapy with PDE5i, ERA, and/or oral prostacyclin pathway agents
- WHO FC improvement from IV to III; resumption of some activities; the "new normal" of living with PAH
- The prostacyclin pump added when oral therapy was insufficient — the years of living with the backpack; the work modifications; the identity shift
- Regular PAH center visits, serial RHCs, 6MWT monitoring — the disease managed but not cured
MOS
6–18
6–18
Phase 3 — Functional Decline
- 6MWT decreasing each year despite medication optimization; second- and third-line agents added
- Syncope begins — the most terrifying symptom; the 911 calls; the restrictions on driving and activities
- Hospitalizations for acute RV decompensation — IV diuretics, inotropic support, ICU admissions
- Lung transplant evaluation — the only curative option; the decision between transplant listing and comfort-directed care; some patients decline or are not candidates
- WHO FC IV reached — dyspnea at rest, near-total exertional limitation, the disease has outpaced the medications
WKS–
MOS
MOS
Phase 4 — Active Hospice Enrollment
- Prostacyclin pump protocol verified at enrollment; REVEAL 2.0 score documented for hospice eligibility
- All PAH medications continued; PAH specialist co-management established
- Morphine initiated for dyspnea; precision diuresis calibrated; fan therapy ordered
- Syncope advance directive completed; ICD deactivation conversation; BMPR2 genetic counseling referral
- Family education: pump emergency protocol, volume management, medication safety, syncope response
- Psychosocial support activated — the young family support; the reproductive grief; the pump identity work
HRS–
DAYS
DAYS
Phase 5 — Terminal Transition & Final Hours
- Progressive low-output state: worsening fatigue, somnolence, declining urine output, rising creatinine, hepatic congestion
- The prostacyclin pump comfort transition decision — the specialist-guided conversation about whether to continue or wean
- Increasing dyspnea at rest — morphine titration, fan therapy, positioning; midazolam available for refractory distress
- Risk of terminal arrhythmia — ICD deactivation must be completed before this phase; magnet at bedside if not yet deactivated
- The final hours: Cheyne-Stokes breathing or agonal breathing; mottling; unresponsive; the family who has been the pump technician for years now transitions to simply being present
- The young children's goodbye; the partner who sets down the cassette-changing gloves; the family who has been caring for a 38-year-old with a backpack for the last six years
Medications to Anticipate
PAH-specific pharmacology for the hospice team. Disease-directed medications that ARE comfort medications, plus symptom management for the failing RV.
🚨 Four Non-Negotiable Safety Acts Before Any Other Clinical Assessment
- (1) PROSTACYCLIN PUMP VERIFIED at enrollment and at every subsequent visit — dose, cassette, battery, catheter, home infusion contact. The pump that fails without a plan kills.
- (2) NO NITRATES WITH SILDENAFIL OR TADALAFIL — ABSOLUTELY CONTRAINDICATED. Post this as prominently as morphine in ESRD.
- (3) NO RIOCIGUAT WITH PDE5 INHIBITORS — absolutely contraindicated from additive hypotension. If both present, call PAH specialist immediately.
- (4) CONSULT PAH SPECIALIST BEFORE MODIFYING ANY PAH MEDICATION — all produce rebound vasoconstriction on abrupt withdrawal. Never stop any PAH medication without a transition plan from the PAH specialist.
| Drug | Class / Target | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Epoprostenol (Flolan/Veletri) | Prostacyclin analog / IV continuous | Established ng/kg/min dose — DO NOT MODIFY | NEVER INTERRUPT for more than 5 minutes. Document current dose, cassette schedule, battery protocol, emergency contact, backup supply. The most critical medication in PAH hospice. Comfort-benefit reassessment at terminal transition is a PAH specialist-guided decision.[16] |
| Treprostinil (Remodulin) | Prostacyclin analog / IV or SQ continuous | Established dose — DO NOT MODIFY | Longer half-life (~4 hrs IV, 3–4 hrs SQ) than epoprostenol — slightly larger safety window. SQ route avoids CVC/CRBSI risk but causes infusion site pain. Same never-interrupt principle applies.[36] |
| Sildenafil (Revatio) | PDE5i / Pulmonary vasodilator | 20 mg PO TID — continue at established dose | ⚠ NEVER combine with nitrates. NEVER combine with riociguat. Do not stop abruptly — rebound vasoconstriction. Bosentan reduces sildenafil levels via CYP3A4 induction.[18] |
| Tadalafil (Adcirca) | PDE5i / Pulmonary vasodilator | 40 mg PO daily — continue at established dose | Same nitrate and riociguat contraindications as sildenafil. Longer half-life allows once-daily dosing. Same rebound risk on abrupt withdrawal. |
| Bosentan (Tracleer) | Dual ERA / Endothelin antagonist | 125 mg PO BID — continue at established dose | CYP3A4/2C9 inducer — reduces levels of sildenafil, warfarin, many supplements. Monthly LFTs. Hepatotoxicity risk. Do not stop abruptly — ET-1 rebound.[19] |
| Macitentan (Opsumit) | ERA / Endothelin antagonist | 10 mg PO daily — continue | Fewer CYP interactions than bosentan. Monitor Hgb (anemia). Do not stop abruptly. |
| Riociguat (Adempas) | sGC stimulator / NO-sGC-cGMP pathway | Established dose (max 2.5 mg TID) | ⚠ ABSOLUTELY CONTRAINDICATED with PDE5i. If both present in med list — call PAH specialist immediately. Hypotension, GI upset common.[20] |
| Selexipag (Uptravi) | Oral IP receptor agonist / Prostacyclin pathway | Established dose (max 1600 mcg BID) | Headache, jaw pain, diarrhea, nausea common. Do not stop abruptly. Continue at established dose unless GI symptoms intolerable at end of life. |
| Furosemide | Loop diuretic / Volume management | 20–40 mg PO daily | PRECISION DIURESIS — not aggressive. Monitor BMP weekly. Over-diuresis causes low-output state from inadequate RV preload. Signs: worsening fatigue, hypotension, rising creatinine.[23] |
| Spironolactone | MRA / Aldosterone antagonist | 25 mg PO daily | Potassium-sparing adjunct to furosemide. Potential RV remodeling benefit. Monitor K⁺. Avoid if K⁺ >5.0 or creatinine rapidly rising. |
| Morphine | Opioid / Dyspnea + Pain | 2.5 mg PO q4h PRN | First-line for PAH dyspnea. Start lower than COPD dose due to hemodynamic sensitivity. Titrate to effect. Slight PVR reduction is beneficial in PAH. Add bowel regimen on day one.[24] |
| Lorazepam | Benzodiazepine / Anxiety | 0.5 mg PO/SQ q6h PRN | Adjunctive for anxiety component of dyspnea. Avoid scheduled use unless breakthrough is frequent. Caution in hemodynamically fragile patients — may reduce preload. |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN | Terminal agitation and catastrophic symptom management. Have in comfort kit drawn and labeled. Consider CSCI 10–30 mg/24h for refractory terminal distress. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Have in comfort kit. |
| Digoxin | Cardiac glycoside / RV inotropy | 0.125 mg PO daily if on established dose | Controversial in PAH; some patients have been on low-dose digoxin for years. Continue if stable and no toxicity. Do not initiate de novo at hospice enrollment. Monitor for toxicity (GI, arrhythmia) especially with declining renal function. |
🌿 PAH-Specific Symptom Management Decision Tree
Evidence-based · PAH-adapted · Hospice-focusedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for PAH
- Pump failure: Written pump emergency protocol posted at bedside; backup cassette and battery verified; home infusion emergency number posted
- Acute dyspnea crisis: Morphine 5 mg SQ pre-drawn; midazolam 5 mg SQ pre-drawn and labeled; fan at bedside
- Syncope event: Syncope advance directive accessible; Trendelenburg positioning protocol posted; 911 instructions per patient preference
- Terminal agitation: Midazolam 5 mg SQ × 3 doses pre-drawn; haloperidol 2 mg SQ × 3 doses pre-drawn
- Terminal secretions: Glycopyrrolate 0.2 mg SQ × 6 doses pre-drawn
- ICD shock prevention: Magnet at bedside if ICD not yet deactivated; deactivation referral documented
Clinician Pointers
High-yield clinical pearls for the hospice team managing end-stage PAH. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Verify the prostacyclin pump at every visit before anything else
The five-step pump check (dose, cassette, battery, catheter, home infusion contact) is the first clinical act at every PAH hospice visit. The pump that fails without a plan kills within minutes for epoprostenol or hours for IV treprostinil. Document the verification in every visit note. No exceptions.
2
Contact the PAH specialist at or before enrollment
The PAH center that has been managing this patient has disease-specific expertise that the hospice team needs. Call them. Document the specialist name and contact in the care plan. Every PAH medication decision should run through this specialist. The PAH center's NP or coordinator who has been managing this patient for years has clinical knowledge that is irreplaceable.
3
Titrate diuretics with the PAH preload paradox in mind
The JVP, the BNP trend, and the renal function are the clinical guides. The patient who becomes more fatigued after a diuretic increase is being over-diuresed. Reduce the dose and reassess. The JVP that is mild-to-moderately elevated in PAH is the appropriate filling pressure for this patient — the JVP that collapses to zero after diuresis has removed the preload the RV was using to maintain output.[23]
4
Complete the syncope advance directive at enrollment
Specifically ask about hospitalization for syncope, CPR for syncope-to-arrest, and ICD deactivation. The syncope that occurs without a documented advance directive results in 911 activation and potentially unwanted interventions. Document the decision before the first syncope event, not during it.
5
Refer for BMPR2 genetic counseling at enrollment
The first-degree relatives of the patient with IPAH or HPAH have a 5–10% absolute risk of developing PAH if they carry the BMPR2 mutation. Early diagnosis saves lives. The referral made at enrollment is the referral that happens before the patient's death removes the opportunity. Document the referral and the family's response.[14]
6
Prescribe morphine for dyspnea at the first visit
Start at 2.5 mg PO q4h PRN — lower than the COPD starting dose because the hemodynamically compromised RV is more sensitive to vasodilatory effects. The opioid for the dyspnea of low-cardiac-output PAH that has been unmanaged. Fan therapy as a formal co-prescription. Titrate based on dyspnea response and hemodynamic tolerance.[24]
7
Know the sildenafil-nitrate contraindication — and post it
The sildenafil-nitrate combination is as absolutely contraindicated as any drug interaction in medicine. Post it in the care plan, on the medication safety sheet, and in the communication to every on-call clinician. The on-call nurse who prescribes nitroglycerin for chest pain in a PAH patient on sildenafil will cause a potentially fatal hypotensive crisis. Every member of the care team must know this.[27]
8
Initiate the ICD deactivation conversation early
The ICD that fires during the dying process causes suffering. The conversation about deactivation — either by reprogramming or magnet placement — should happen at enrollment. If the patient declines deactivation, have the magnet at bedside for the family to apply if shocks occur during active dying. Document clearly.
9
Address pregnancy counseling for reproductive-age women
PAH carries 30–50% maternal mortality in pregnancy. Even at end-stage, the conversation about contraception or the grief of reproductive loss may be relevant — the patient who was diagnosed at 28 and told she could never carry a pregnancy has lived with that grief for years. Open the door: "Has anyone ever talked with you about what the diagnosis meant for having children?"
10
Screen for and address racial/ethnic disparities in PAH care
Black and Hispanic patients with PAH are diagnosed later, receive fewer PAH-targeted therapies, have less access to PAH specialty centers, and have worse outcomes. The hospice clinician's role: ensure equal access to the prostacyclin pump support, the PAH specialist co-management, the genetic counseling referral, and the psychosocial support regardless of race, ethnicity, or insurance status.[37]
11
Consider spironolactone as a diuretic adjunct
Spironolactone 25 mg daily provides potassium-sparing diuresis (reducing hypokalemia risk from furosemide), potential RV remodeling benefit through aldosterone receptor blockade, and reduces the need for potassium supplementation. Monitor potassium carefully, especially as renal function declines from low cardiac output.[28]
12
Plan the prostacyclin pump comfort transition before the crisis
The decision to wean or discontinue the prostacyclin pump at the terminal stage should be discussed early in the enrollment — not during a pump emergency. This is a PAH specialist-guided decision made in collaboration with the patient and family. When the decision is made, the wean is gradual over hours to days with comfort medications titrated to manage symptoms. The family needs advance preparation for what the transition will look like.
"The hardest conversation in PAH hospice isn't about the pump or the medications — it's about the children. This woman is 37 with a 4-year-old and a 7-year-old, and the 7-year-old knows what the backpack is. The conversation about what to tell the children — that's the one you prepare for, and it's the one that no amount of clinical training fully prepares you for. Bring your social worker. Bring your chaplain. Don't do it alone."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
The young female population, the pump as identity, the children who know about the pump but not about dying, and the specific grief landscape of end-stage PAH.
The psychosocial landscape of end-stage PAH is unlike any other hospice diagnosis. The typical PAH patient is a woman in her 30s to 50s — dying at an age when most hospice patients are decades older. She may have young children, a career that was interrupted by the disease, a partner who has been managing the pump and the caregiving simultaneously, and a reproductive history shaped by the 30–50% maternal mortality that made pregnancy impossible. The chaplain, the social worker, and the clinician must understand these PAH-specific dimensions to provide adequate psychosocial care.[38]
The Predominantly Young Female Population
PAH predominantly affects women in the third to fifth decade of life. The hospice patient with end-stage PAH may be 32 or 38 or 45, with young children, with a career that was interrupted, with a partner who has been carrying the weight of clinical caregiving for years. The specific grief of dying young — the same framework as sarcoma (Card #61) and DMD (Card #64) but with the PAH-specific dimension of a disease that arrived in the midst of building a family and a life — requires age-appropriate psychosocial support that most hospice teams are not accustomed to providing for their typical patient population.
The Pump as Identity
The patient who has worn a prostacyclin pump for 4 or 6 or 8 years has integrated that backpack into their identity as completely as any other aspect of their life. It is in every photograph, at every family event, during every intimate moment. The chaplain who creates space for the meaning of the pump — "What has it been like to carry this pump for the past six years?" — opens a conversation about identity, about living with chronic dependence on a device, and about the specific grief of what the pump has made possible and what it has cost. The pump transition conversation at end of life is not just a clinical decision — it is an identity transition.
The Children Who Know About the Pump
Child & Sibling Support
The young children of the PAH patient have grown up knowing that mom has a "heart pump" but may not understand what WHO FC IV means. Age-appropriate information, facilitation of age-appropriate involvement, the school counselor connection, and memory-making at the first visit are all essential. The 7-year-old who has been told "mommy's pump keeps her heart working" needs a developmentally appropriate explanation of what is happening now — and the parent needs help formulating that explanation.
The Partner as Home Infusion Technician
The partner who has been changing the prostacyclin cassette every 24 hours, troubleshooting pump alarms at 3 AM, and carrying the weight of clinical caregiving for years has a unique form of caregiver burden. They are simultaneously the medical technician, the emotional support, the co-parent, and the person watching their partner die. When the pump transition occurs, the partner loses not just the caregiving role but the one thing they felt they could control. Anticipatory grief support must address this loss of agency specifically.
Reproductive Grief & BMPR2 Guilt
Reproductive grief: The woman diagnosed with PAH in her reproductive years was told that pregnancy carries 30–50% maternal mortality. The decision to forgo childbearing — or the grief of a pregnancy that could never happen — is a wound that may never have been fully addressed. At end of life, this grief can surface powerfully: "I never got to have a second child." The clinician who recognizes this grief and creates space for it provides care that no medication can offer.
BMPR2 guilt and carrier testing: For patients with heritable PAH, the knowledge that they may have passed the BMPR2 mutation to their children creates a specific form of parental guilt that is clinically significant. The genetic counseling referral at enrollment addresses both the medical imperative (testing can save the children's lives) and the psychosocial need (the parent needs to know that the referral has been made). The parent who dies without knowing whether their children carry the mutation may carry that uncertainty as unfinished business.[14]
Transplant Grief & Registry Connections
Many PAH patients were evaluated for lung transplant — the only curative option. The patient who was listed and then delisted as the disease progressed, or who was never a candidate, carries a specific grief: the hope that was offered and then removed. The transition from "waiting for transplant" to "enrolling in hospice" is one of the most difficult psychological transitions in all of medicine. Support groups (Pulmonary Hypertension Association — PHA) and the PAH patient registry can provide connection and validation during this transition.
Racial & Ethnic Disparities in PAH
Black and Hispanic patients with PAH are diagnosed later, receive fewer PAH-targeted therapies, have less access to PAH specialty centers, and have worse outcomes compared to White patients. These disparities are documented in REVEAL and other registries. The hospice clinician must actively work to ensure that every patient — regardless of race, ethnicity, language, or insurance status — receives the same level of pump support, specialist co-management, genetic counseling referral, and psychosocial care.[37]
Clinical Pearl
"The PAH patient who has been connected to a pump for years has a relationship with that device that is more intimate than most people have with any object in their life. When the conversation turns to discontinuing the pump, you are not just talking about a medication change. You are talking about removing a part of their identity. Treat it with that gravity."
"I had a 34-year-old PAH patient with twin 5-year-olds. Her husband had been changing the cassette every morning for three years. When we talked about the pump transition, he broke down — not because of the medical implications, but because the cassette change was the one thing he could do for her every day. When that was gone, he didn't know how to be useful anymore. That's the conversation you prepare for."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. THE PUMP IS THE MOST IMPORTANT THING IN THIS HOUSE. Share, print, or read aloud at the bedside.
Your person has a condition called pulmonary hypertension — high blood pressure in the lungs that has made the right side of the heart work too hard for too long. The heart has reached a point where, despite all the medications and the pump, it can no longer keep up with the demands the lungs are placing on it. We are here to help manage symptoms, keep your person comfortable, and support your entire family through this time. You are not alone in this, and there are specific things you can do that genuinely help.
💉 THE PUMP IS THE MOST IMPORTANT THING IN THIS HOUSE
Your person's infusion pump delivers a medication that keeps the blood vessels in their lungs open. Without it, the blood pressure in the lungs would rise rapidly and the heart would fail within minutes to hours.
- Never let the pump stop without immediately trying to restart it
- Never let the cassette expire — change it on schedule
- Never let the battery die — keep the backup battery fully charged
- Know the alarm sounds and what each one means
- Keep the emergency contact number for the infusion company accessible at all times
🚨 IF THE PUMP ALARMS AND CANNOT BE RESTARTED
- Step 1: Try to restart the infusion using the steps on the pump instruction card
- Step 2: Call the home infusion company emergency line immediately
- Step 3: Call the hospice nurse
- Step 4: If the infusion cannot be restarted within 15 minutes — take your person to the emergency department now, bringing this card which explains the IV prostacyclin emergency. This is not a drill. This situation requires immediate action.
About the Volume and Swelling
- Your person has fluid buildup from the strain on the right side of the heart. We are using a water pill (diuretic) to reduce this fluid.
- Unlike most heart failure patients, your person's heart depends on having enough fluid to pump — if we give too much water pill, it can actually make the heart work worse by reducing the blood available for pumping.
- If your person seems more tired, dizzy, or their blood pressure seems low after taking more water pill — call the hospice nurse before the next dose. We may need to reduce the amount.
- Some swelling in the legs and belly is expected and does not always need to be treated aggressively. We are balancing comfort with heart function.
About Fainting (Syncope)
- Fainting spells can happen when the heart cannot pump enough blood to the brain during moments of increased demand — standing up quickly, straining, or even coughing.
- If your person faints: Lay them flat or with legs elevated. Do not try to sit them up. Call the hospice nurse. If they do not regain consciousness within 2 minutes, follow the advance directive plan you discussed with your hospice team.
- Prevent falls: Remove trip hazards. Assist with standing. Have your person sit on the edge of the bed before standing. A commode by the bed reduces the walk to the bathroom.
- This is not the same as ordinary fainting. In pulmonary hypertension, fainting means the heart could not pump enough blood. It is a serious symptom.
Medication Safety
- NEVER give nitroglycerin (or any "nitrate" heart medication) to your person if they are taking sildenafil or tadalafil. This combination causes a dangerous drop in blood pressure. If chest pain occurs, call the hospice nurse — do NOT give nitroglycerin.
- Do not stop any medication without talking to the hospice nurse or the PAH specialist first. These medications are keeping the blood vessels in the lungs open. Stopping them suddenly can cause a crisis.
- Check with the nurse before adding any supplements, vitamins, or herbal products. Some "natural" products interact dangerously with pulmonary hypertension medications.
Emotional Support for Young Families
- It's okay to not be okay. Caring for a young person with this condition — managing the pump, watching the symptoms, raising children — is an extraordinary burden. You deserve support too.
- Talk to your children at their level. The social worker and chaplain can help you find the right words. Children do better when they have honest, age-appropriate information rather than silence.
- The Pulmonary Hypertension Association (PHA) has support groups for patients and families: PHAssociation.org
- Ask for help. You have been the caretaker, the technician, and the partner. Let the hospice team carry some of that weight now.
📞 Call the nurse immediately if you see:
The pump alarms and cannot be restarted within 5 minutes. Your person faints and does not wake up within 2 minutes. Sudden severe shortness of breath that is different from their usual breathing difficulty. New chest pain. Blue or gray color in the lips or fingertips that is worse than usual. Confusion or difficulty speaking that is new. Swelling that suddenly gets much worse. Any fall. Any bleeding that does not stop.
🙏 You have been carrying something extraordinary — the weight of a pump, a disease, and a family — for years. The fact that you are here, reading this, learning how to help, is an act of love that your person feels even when they cannot say it. You are part of the care team. You matter. And we are here for you, not just for your person.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. Specific to end-stage PAH hospice. Not guidelines — real.
- 01Check the pump before anything else at every single visit. Every visit. The first thing you do when you walk in the door is ask to see the pump. Check the dose, the cassette date, the battery level, the catheter site, the backup supplies. The epoprostenol pump that fails without a backup cassette in the home and without a family who knows the emergency protocol is a preventable death from equipment failure. Document the five-point pump check in every visit note. No exceptions. I've had a cassette expire mid-visit because nobody checked the date. That's a crisis that should never happen.
- 02Call the PAH specialist before or at enrollment — not because you don't know what to do, but because they know this patient's disease and this patient's medications in a way that took years of registry management to accumulate. The PAH center's NP or coordinator who has been managing this patient for six years has clinical knowledge that is irreplaceable. Call them. Get the medication rationale. Get the dose escalation history. Establish the communication protocol for the duration of the enrollment. Document the specialist name and contact in the first line of the care plan. I have never regretted making that call. I have regretted not making it.
- 03Titrate the diuretic with surgical precision. If you see worsening fatigue, rising creatinine, or a drop in systolic blood pressure after a diuretic increase, you have over-diuresed a preload-dependent right ventricle. Reduce the dose. The PAH right heart failure is not the same physiology as left heart failure. The JVP that is mild-to-moderately elevated in PAH is the appropriate right ventricular filling pressure for this patient. The JVP that collapses to zero after diuresis is the signal that you have removed the preload that the RV was using to maintain output. Document the PAH preload-dependence rationale at enrollment and carry it into every diuretic conversation.
- 04Complete the syncope advance directive at enrollment, before any syncope event. I've been in the home when the patient syncopized and the family called 911 because nobody had talked about what to do when it happened. That's our failure, not theirs. Specifically ask: "If you faint and your heart stops, do you want CPR? Do you want to go to the hospital? Do you want us to turn off the defibrillator in your chest?" Get the answers on paper. Get them before the first event. The syncope in WHO FC IV PAH is the hemodynamic equivalent of a cardiac arrest announcement — the cardiac output dropped below the level that perfuses the brain. It will happen again.
- 05Prescribe morphine for dyspnea at the first visit. Not the second visit. Not after you "see how things go." At the first visit. These patients have been short of breath for months or years and nobody has treated the dyspnea because everyone was focused on the PAH medications. Start at 2.5 mg oral q4h PRN — lower than what you'd use for COPD because the hemodynamically compromised RV is more sensitive. Add the fan. Add the supplemental oxygen if SpO₂ is below 90. The Abernethy evidence applies here. The patient who has been suffering from dyspnea without opioid management has been suffering unnecessarily.
- 06Know the nitrate-sildenafil contraindication cold, and make sure every person on your team knows it too. The on-call nurse who gets a 2 AM call about chest pain in a PAH patient and reaches for the nitroglycerin without checking the medication list will cause a potentially fatal crisis. This is the most dangerous drug interaction in PAH hospice. Post it in the care plan. Put it on the medication safety sheet. Say it out loud at every team meeting. Nitroglycerin, isosorbide mononitrate, isosorbide dinitrate — none of them, ever, in a patient on sildenafil or tadalafil. No exceptions.
- 07Talk to the children early. The 7-year-old who has grown up with mom's backpack understands more than you think and less than they need. The social worker and the chaplain should be in the home by the second visit, and the conversation about what to tell the children should happen before the child walks in from school and sees their parent in crisis. Use the language the family uses — "mommy's heart pump," "the medicine backpack" — and build from there. Memory-making at the first visit. Handprints, letters, video recordings. Do not wait. The families who regret something almost always regret not starting the memory work sooner.
- 08Screen for disparities actively. Black and Hispanic PAH patients are diagnosed later, receive fewer PAH-targeted therapies, and have worse outcomes. When you walk into the home, ask yourself: Is this patient getting the same level of pump support, specialist co-management, and psychosocial care that a White patient in the same zip code would receive? If the answer is no, fix it. The REVEAL registry data shows the disparity. The hospice clinician at the bedside is the one person who can correct it in real time.
- 09Take care of the caregiver who has been the home infusion technician. The partner who has been changing the prostacyclin cassette every 24 hours, who has been troubleshooting pump alarms at 3 AM, who has been managing a household and children while being the de facto medical professional — that person is burned out in a way that most hospice caregivers are not. They carry the specific weight of knowing that if they make a mistake with the cassette, their partner could die. When you assess the caregiver, assess for this specific burden. Offer respite. Offer the PHA caregiver support line. Acknowledge what they have been doing. They need to hear someone say it out loud.
- 10Remember that this patient has been living with a death sentence and a backpack for years. She has fought harder than most patients you will ever meet. She has worn that pump to work, to her child's school play, to her anniversary dinner. She has managed a disease that most clinicians have never heard of, in a body that is decades younger than your average hospice patient. When you sit down at her bedside, know that you are sitting with someone who has earned every moment of comfort and every ounce of respect that you can offer. Check the pump, manage the symptoms, support the family — and be present. That's the whole job. And it matters.
— Waldo, NP
References
Peer-reviewed citations organized by clinical category. All PMIDs hyperlinked. Evidence levels assigned by study design.
PAH Epidemiology & Classification
1
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731.
2
D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
3
Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–335.
4
Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128–137.
5
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.
6
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387.
WHO Functional Classification & Prognosis
7
McLaughlin VV, Langer A, Tan M, et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest. 2013;143(2):324–332.
8
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–D50.
9
Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–456.
10
Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–1041.
11
Tuder RM, Archer SL, Dorfmuller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D4–D12.
12
Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12):4306–4313.
RV Failure, Volume Management & Hemodynamics
13
Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol. 2017;69(2):236–243.
23
Lahm T, Douglas IS, Archer SL, et al. Assessment of right ventricular function in the research setting: knowledge gaps and pathways to progress. Am J Respir Crit Care Med. 2018;198(4):e15–e43.
28
Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the ARIES Study). Am J Cardiol. 2013;112(5):720–725.
Prostacyclin Therapy & Pump Management
14
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26(1):81–84.
15
Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000;37(10):741–745.
16
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.
17
Rich JD, Archer SL, Rich S. Noninvasive cardiac output measurements validate hemodynamic assessment by right heart catheterization. PLoS One. 2013;8(2):e56850.
36
Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(6):800–804.
39
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482.
40
Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586–1589.
PAH-Targeted Pharmacotherapy
18
Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension (SUPER study). N Engl J Med. 2005;353(20):2148–2157.
19
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–1123.
20
Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension (PATENT-1). N Engl J Med. 2013;369(4):330–340.
21
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension (SERAPHIN). N Engl J Med. 2013;369(9):809–818.
22
Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension (AMBITION). N Engl J Med. 2015;373(9):834–844.
41
Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension (GRIPHON). N Engl J Med. 2015;373(26):2522–2533.
27
Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42(10):1855–1860.
42
Paul GA, Gibbs JSR, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60(1):107–112.
Palliative Care in PAH & Dyspnea Management
24
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.
25
Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010;39(5):831–838.
26
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250–2294.
29
Fenstad ER, Le RJ, Sinak LJ, et al. Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. Chest. 2013;144(5):1530–1538.
30
Graarup J, Ferrari P, Howard LS. Patient engagement and self-management in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):399–407.
31
Bradt J, Dileo C, Magill L, Teague A. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev. 2016;(8):CD006911.
43
Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24(138):621–629.
44
Kingman M, Hinzmann B, Sweet O, Vachiéry JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open Respir Res. 2014;1(1):e000007.
Syncope, Arrhythmia & ICD Management
45
Tonelli AR, Arelli V, Minai OA, et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(3):365–369.
46
Olsson KM, Nickel NP, Guth S, et al. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013;167(5):2300–2305.
47
Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011;184(10):1114–1124.
48
Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation. 1994;89(4):1733–1744.
BMPR2 Genetics & Heritable PAH
49
Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) or a BMPR2 mutation. Am J Respir Crit Care Med. 2010;181(8):851–861.
50
Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res. 2014;115(1):189–202.
SSc-PAH & CTD-PAH
32
Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151–157.
33
Ruiter G, Lanser IJ, de Man FS, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology. 2014;53(2):285–292.
51
Hachulla E, Carpentier P, Gressin V, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology. 2009;48(3):304–308.
Oxygen, Reproductive Counseling & Eisenmenger
34
Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164(9):1682–1687.
35
Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31(7):1650–1657.
37
Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752–759.
38
Galiè N, Humbert M, Vachiéry JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67–119.
52
Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome (BREATHE-5). Circulation. 2006;114(1):48–54.
53
Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112(6):828–835.
54
Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol. 2003;42(7):1982–1987.
55
Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.